• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/2/21 3:14:13 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    SC 13G/A 1 west20a2.htm west20a2.htm - Generated by SEC Publisher for SEC Filing  

          CUSIP NO. 955306105                           13G                            Page 1 of 14

     

     

                                                                                 UNITED STATES

                                                            SECURITIES AND EXCHANGE COMMISSION

                                                                        Washington, D.C. 20549

     

                                                                                  SCHEDULE 13G

     

                                                     Under the Securities Exchange Act of 1934

                                                                            (Amendment No. 2)*

     

                                                            WEST PHARMACEUTICAL SERVICES, INC.

                                                                              (Name of Issuer)

     

                                                       Common Stock, par value $0.25 per share

                                                                (Title of Class of Securities)

     

                                                                                     955306105

                                                                                (CUSIP Number)

     

                                                                             December 31, 2020

     

                                       (Date of Event Which Requires Filing of this Statement)

     

        Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

        [X] Rule 13d‑1(b)

        [ ] Rule 13d‑1(c)

        [ ] Rule 13d‑1(d)

     

        *The remainder of this cover page shall be filled out for a reporting person's initial

        filing on this form with respect to the subject class of securities, and for any

        subsequent amendment containing information which would alter the disclosures provided in

        a prior cover page.

     

        The information required in the remainder of this cover page shall not be deemed to be

        "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or

        otherwise subject to the liabilities of that section of the Act but shall be subject to

        all other provisions of the Act (however, see the Notes).

     


     
     

          CUSIP NO. 955306105                           13G                            Page 2 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Resources, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          Delaware

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          (See Item 4)

     

              6.    SHARED VOTING POWER

     

                          (See Item 4)

     

              7.    SOLE DISPOSITIVE POWER

     

                          (See Item 4)

     

              8.    SHARED DISPOSITIVE POWER

     

                          (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          3,854,278

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          5.2%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, CO (See Item 4)

     


     
     

          CUSIP NO. 955306105                           13G                            Page 3 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Charles B. Johnson

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          (See Item 4)

     

              6.    SHARED VOTING POWER

     

                          (See Item 4)

     

              7.    SOLE DISPOSITIVE POWER

     

                          (See Item 4)

     

              8.    SHARED DISPOSITIVE POWER

     

                          (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          3,854,278

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          5.2%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


     
     

          CUSIP NO. 955306105                           13G                            Page 4 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Rupert H. Johnson, Jr.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          (See Item 4)

     

              6.    SHARED VOTING POWER

     

                          (See Item 4)

     

              7.    SOLE DISPOSITIVE POWER

     

                          (See Item 4)

     

              8.    SHARED DISPOSITIVE POWER

     

                          (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          3,854,278

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          5.2%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


     
     

          CUSIP NO. 955306105                           13G                            Page 5 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Advisers, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          California

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          3,795,082

     

              6.    SHARED VOTING POWER

     

                          0

     

              7.    SOLE DISPOSITIVE POWER

     

                          3,795,930

     

              8.    SHARED DISPOSITIVE POWER

     

                          840

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          3,796,770

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          5.1%

     

              12.   TYPE OF REPORTING PERSON

     

                          IA, CO (See Item 4)

     


     
     

          CUSIP NO. 955306105                           13G                            Page 6 of 14

     

     

              Item 1.

     

              (a)   Name of Issuer

     

                          WEST PHARMACEUTICAL SERVICES, INC.

     

              (b)   Address of Issuer's Principal Executive Offices

     

                          530 Herman O. West Drive

               Exton, PA 19341-0645

     

     

              Item 2.

     

              (a)   Name of Person Filing

                          (i):   Franklin Resources, Inc.

     

                          (ii):  Charles B. Johnson

     

                          (iii): Rupert H. Johnson, Jr.

     

                          (iv):  Franklin Advisers, Inc.

     

     

              (b)   Address of Principal Business Office or, if none, Residence

     

                          (i), (ii), and (iii):

                                      One Franklin Parkway

                                      San Mateo, CA 94403‑1906

                         (iv): One Franklin Parkway

                                      San Mateo, CA  94403‑1906

     

              (c)   Citizenship

     

                          (i):     Delaware

     

                          (ii) and (iii): USA

     

                          (iv): California

     

     

              (d)   Title of Class of Securities

     

                          Common Stock, par value $0.25 per share

     

              (e)   CUSIP Number

     

                          955306105

     


     
     

          CUSIP NO. 955306105                           13G                            Page 7 of 14

            Item 3. If this statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c),

                            check whether the person filing is a:

                          (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

                          (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

                          (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.

                                          78c).

     

                          (d) [ ] Investment company registered under section 8 of the Investment Company

                                          Act of 1940 (15 U.S.C 80a‑8).

     

                          (e) [X] An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);

     

                          (f) [ ] An employee benefit plan or endowment fund in accordance with

                                          §240.13d‑1(b)(1)(ii)(F);

     

                          (g) [X] A parent holding company or control person in accordance with

                                          §240.13d‑1(b)(1)(ii)(G);

     

                          (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit

                                          Insurance Act (12 U.S.C. 1813);

     

                          (i) [ ] A church plan that is excluded from the definition of an investment

                                          company under section 3(c)(14) of the Investment Company Act of 1940 (15

                                          U.S.C. 80a‑3);

     

                          (j) [ ] A non‑U.S. institution in accordance with §240.13d‑1(b)(ii)(J);

     

                          (k) [ ] Group, in accordance with §240.13d 1(b)(1)(ii)(K).

     

                          If filing as a non‑U.S. institution in accordance with §240.13d‑1(b)(1)(ii) (J).

                          please specify the type of institution:

     

              Item 4.  Ownership

     

              The securities reported herein are beneficially owned by one or more open or closed end

         investment companies or other managed accounts that are investment management clients of

         investment managers that are direct and indirect subsidiaries (each, an “Investment

         Management Subsidiary” and, collectively, the “Investment Management Subsidiaries”) of

         Franklin Resources Inc. (“FRI”), including the Investment Management Subsidiaries listed

         in this Item 4.  When an investment management contract (including a sub advisory

         agreement) delegates to an Investment Management Subsidiary investment discretion or

         voting power over the securities held in the investment advisory accounts that are

         subject to that agreement, FRI treats the Investment Management Subsidiary as having sole

         investment discretion or voting authority, as the case may be, unless the agreement

         specifies otherwise. Accordingly, each Investment Management Subsidiary reports on

         Schedule 13G that it has sole investment discretion and voting authority over the

         securities covered by any such investment management agreement, unless otherwise noted in

         this Item 4.  As a result, for purposes of Rule 13d-3 under the Act, the Investment

         Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners

         of the securities reported in this Schedule 13G.

     

         Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is

         being reported in conformity with the guidelines articulated by the SEC staff in Release

         No. 34-39538 (January 12, 1998) (the “1998 Release”) relating to organizations, such as

         FRI, where related entities exercise voting and investment powers over the securities

         being reported independently from each other.  The voting and investment powers held by

         each of FRI’s affiliates whose ownership of securities is disaggregated from that of FRI

         in accordance with the 1998 Release (“FRI Disaggregated Affiliates”) are exercised

         independently from FRI and from all other Investment Management Subsidiaries (FRI, its

         affiliates and the Investment Management Subsidiaries other than FRI Disaggregated

         Affiliates are collectively, “FRI Aggregated Affiliates”). Furthermore, internal policies

         and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand,

         FRI establish informational barriers that prevent the flow among, on the one hand, FRI

         Disaggregated Affiliates (including preventing the flow between such entities), and, on

         the other hand, the FRI Aggregated Affiliates of information that relates to the voting


     
     

     

     

          CUSIP NO. 955306105                           13G                            Page 8 of 14

     

              and investment powers over the securities owned by their respective investment management

         clients.

     

         Consequently, FRI Disaggregated Affiliates report the securities over which they hold

         investment and voting power separately from the FRI Aggregated Affiliates for purposes of

         Section 13 of the Act.

     

              Charles B. Johnson and Rupert H. Johnson, Jr. (the “Principal Shareholders”) each own in

              excess of 10% of the outstanding common stock of FRI and are the principal stockholders

              of FRI.  FRI and the Principal Shareholders may be deemed to be, for purposes of Rule

              13d‑3 under the Act, the beneficial owners of securities held by persons and entities for

              whom or for which FRI subsidiaries provide investment management services.  The number of

              shares that may be deemed to be beneficially owned and the percentage of the class of

              which such shares are a part are reported in Items 9 and 11 of the cover pages for FRI

              and each of the Principal Shareholders.  FRI, the Principal Shareholders and each of the

              Investment Management Subsidiaries disclaim any pecuniary interest in any of such

              securities.  In addition, the filing of this Schedule 13G on behalf of the Principal

              Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be

         construed as an admission that any of them is, and each of them disclaims that it is, the

         beneficial owner, as defined in Rule 13d‑3, of any of the securities reported in this

         Schedule 13G.

     

              FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries

              believe that they are not a “group” within the meaning of Rule 13d‑5 under the Act and

              that they are not otherwise required to attribute to each other the beneficial ownership

              of the securities held by any of them or by any persons or entities for whom or for which

              the Investment Management Subsidiaries provide investment management services.

     

                          (a)   Amount beneficially owned:

     

                                      3,854,278

     

                          (b)   Percent of class:

     

                                      5.2%

     

                          (c)   Number of shares as to which the person has:

     

                                  (i)  Sole power to vote or to direct the vote

     

                                            Franklin Resources, Inc.:                                          0

     

                                            Charles B. Johnson:                                                0

     

                                            Rupert H. Johnson, Jr.:                                            0

     

                                            Franklin Advisory Services, LLC:                              11,520

     

                                            Franklin Advisers, Inc.:                                   3,795,082

     

                                            Franklin Templeton Investments (Asia) Ltd.:                   20,847

     

                                            Franklin Templeton International Services S.à r.l.:            3,272

     

                                            Fiduciary Trust Company International:                            90

     

                                            Fiduciary Trust International, LLC:                              807

     

                                            Fiduciary Trust Co International of Pennsylvania:             20,972

     

     


     
     

          CUSIP NO. 955306105                           13G                            Page 9 of 14

     

                                (ii)  Shared power to vote or to direct the vote

     

                                            0

     

     

                              (iii)  Sole power to dispose or to direct the disposition of

     

                                            Franklin Resources, Inc.:                                          0

     

                                            Charles B. Johnson:                                                0

     

                                            Rupert H. Johnson, Jr.:                                            0

     

                                            Franklin Advisers, Inc.:                                   3,795,930

     

                                            Fiduciary Trust Co International of Pennsylvania:             20,972

     

                                            Franklin Templeton Investments (Asia) Ltd.:                   20,847

     

                                            Franklin Advisory Services, LLC:                              11,520

     

                                            Franklin Templeton International Services S.à r.l.:            3,272

     

                                            Fiduciary Trust International, LLC:                              807

     

                                            Fiduciary Trust Company International:                            90

     

                               (iv)   Shared power to dispose or to direct the disposition of1

     

                                            Franklin Advisers, Inc.:                                         840

     

              Item 5.  Ownership of Five Percent or Less of a Class

     

                                If this statement is being filed to report the fact that as of the date

                                hereof the reporting person has ceased to be the beneficial owner of more

                                than five percent of the class of securities, check the following [ ].

     

              Item 6.  Ownership of More than Five Percent on Behalf of Another Person

     

                                The clients of the Investment Management Subsidiaries, including investment

                                companies registered under the Investment Company Act of 1940 and other

                                managed accounts, have the right to receive or power to direct the receipt of

                                dividends from, and the proceeds from the sale of, the securities reported

                                herein. 

     

              Item 7.  Identification and Classification of the Subsidiary Which Acquired the

                                Security Being Reported on By the Parent Holding Company

     

                                See Attached Exhibit C

     

              Item 8.  Identification and Classification of Members of the Group

     

                                Not Applicable

     

              Item 9.  Notice of Dissolution of Group

     

                                Not Applicable

     


    1       One or more of the investment management contracts that relates to these securities

              provides that the applicable FRI affiliate share investment power over the securities

              held in the applicable account(s) with another unaffiliated entity. The securities

              held in any such account(s) are less than 5% of the outstanding shares of the class.

              In addition, FRI does not believe that any such contract causes such client or

              unaffiliated entity to be part of a group with FRI or any FRI affiliate within the

              meaning of Rule 13d‑5 under the Act.

     


     
     

          CUSIP NO. 955306105                           13G                            Page 10 of 14

     

              Item 10.  Certification

     

              By signing below I certify that, to the best of my knowledge and belief, the

              securities referred to above were acquired and are held in the ordinary course of

              business and were not acquired and are not held for the purpose of or with the effect

              of changing or influencing the control of the issuer of the securities and were not

              acquired and are not held in connection with or as a participant in any transaction

              having that purpose or effect, other than activities solely in connection

         with a nomination under § 240.14a-11.

     

             

     

              This report shall not be construed as an admission by the persons filing the report

              that they are the beneficial owner of any securities covered by this report.

     

              Exhibits.

                                Exhibit A Joint Filing Agreement

                                Exhibit B Limited Powers of Attorney for Section 13 Reporting Obligations

                                Exhibit C Item 7 Identification and Classification of Subsidiaries

     

                                                                                      SIGNATURE

     

              After reasonable inquiry and to the best of my knowledge and belief, I certify that

              the information set forth in this statement is true, complete and correct.

     

              Dated:  January 25, 2021

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

              Franklin Advisers, Inc.

     

     

              By:    /s/VIRGINIA E. ROSAS

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Virginia E. Rosas

                             Assistant Secretary of Franklin Resources, Inc.

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                Secretary of Franklin Advisers, Inc.

     

     


     
     

          CUSIP NO. 955306105                           13G                            Page 11 of 14

     

              EXHIBIT A

     

              JOINT FILING AGREEMENT

     

              In accordance with Rule 13d‑1(k) under the Securities Exchange Act of 1934, as

              amended, the undersigned hereby agree to the joint filing with each other of the

              attached statement on Schedule 13G and to all amendments to such statement and that

              such statement and all amendments to such statement are made on behalf of each of

              them.

     

              IN WITNESS WHEREOF, the undersigned have executed this agreement on January 25, 2021.

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

              Franklin Advisers, Inc.

     

     

              By:     /s/VIRGINIA E. ROSAS

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Virginia E. Rosas

                             Assistant Secretary of Franklin Resources, Inc.

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                Secretary of Franklin Advisers, Inc.

     

     


     
     

          CUSIP NO. 955306105                           13G                            Page 12 of 14                                                                               

              EXHIBIT B

                                                         LIMITED POWER OF ATTORNEY

    FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

     

              Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Aliya S. Gordon, Steven J. Gray, Kimberly H. Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

     

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

     

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

     

         The undersigned acknowledges that:

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

     

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 8th day of April, 2020.

     

                                                                                                                                  /s/ Charles B. Johnson

                                                                                                                                  Signature

     

                                                                                                                                  Charles B. Johnson     

                                                                                                                                  Print Name


     
     

          CUSIP NO. 955306105                           13G                            Page 13 of 14

     

              LIMITED POWER OF ATTORNEY

    FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

     

         Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Aliya S. Gordon, Steven J. Gray, Kimberly H. Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

     

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

     

         The undersigned acknowledges that:

     

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

     

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 8th day of April, 2020.

     

                                                                                                                            /s/ Rupert H. Johnson, Jr.

                                                                                                                            Signature

     

                                                                                                                            Rupert H. Johnson, Jr.   

                                                                                                                            Print Name

     


     
     

          CUSIP NO. 955306105                           13G                            Page 14 of 14

     

              EXHIBIT C

     

              Franklin Advisers, Inc.                                     Item 3 Classification: 3(e)

     

              Franklin Advisory Services, LLC                             Item 3 Classification: 3(e)

     

              Franklin Templeton Investments (Asia) Ltd.                  Item 3 Classification: 3(e)

     

         Fiduciary Trust Co International of Pennsylvania            Item 3 Classification: 3(e)

     

         Fiduciary Trust Company International                       Item 3 Classification: 3(b)

     

         Fiduciary Trust International, LLC                          Item 3 Classification: 3(e)

     

         Franklin Templeton International Services S.à r.l.          Item 3 Classification: 3(e)

     

     

     

     

    Get the next $WST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    2/7/2024$323.00 → $536.00Hold → Buy
    Jefferies
    6/16/2023$390.00 → $405.00Neutral → Buy
    BofA Securities
    4/11/2023$330.00 → $400.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $WST
    Financials

    Live finance-specific insights

    See more
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host First-Quarter 2025 Conference Call

      EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone particip

      4/10/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    SEC Filings

    See more
    • SEC Form SD filed by West Pharmaceutical Services Inc.

      SD - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/21/25 4:15:15 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/12/25 4:46:53 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/8/25 4:46:47 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $WST
    Leadership Updates

    Live Leadership Updates

    See more
    • Purple Biotech Appoints Shai Lankry as Chief Financial Officer

      U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke

      5/12/25 7:30:00 AM ET
      $GMDA
      $LPTX
      $PPBT
      $WST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • West to Participate in Upcoming Investor Conferences

      EXTON, Pa., May 7, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the BofA Securities Annual Healthcare Conference on Wednesday, May 14, 2025 at 2:20 PM PT. It will also present at the William Blair 45th Annual Growth Stock Conference on Thursday, June 5, 2025 at 10:40 AM CT. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be availabl

      5/7/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • West Announces Executive Leadership Appointments

      EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

      5/12/22 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/13/24 5:17:38 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/14/23 12:37:59 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/10/22 8:47:14 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on West Pharm with a new price target

      Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

      3/18/25 7:58:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00

      2/14/25 7:09:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Citigroup initiated coverage on West Pharm with a new price target

      Citigroup initiated coverage of West Pharm with a rating of Buy and set a new price target of $400.00

      1/8/25 8:35:06 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Campbell Shane Alden

      3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/14/25 4:08:34 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by SVP, Proprietary Segment Campbell Shane Alden

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/14/25 4:04:39 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Michels Douglas A was granted 1,071 shares, increasing direct ownership by 2% to 45,171 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:04:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care